A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration (NOVA-1)
Research Goals
Goal: To evaluate the safety of AR-14034 SR in subjects with neovascular age-related macular degeneration (nAMD) and to evaluate the effect and durability of AR-14034 SR on best corrected visual acuity (BCVA) compared with intravitreal standard of care anti-vascular endothelial growth factor (anti-VEGF) treatment in subjects with nAMD
